PL1848813T3 - Aktywacja glikolipidem bakteryjnym komórek NKT podlegających restrykcji CD1d - Google Patents

Aktywacja glikolipidem bakteryjnym komórek NKT podlegających restrykcji CD1d

Info

Publication number
PL1848813T3
PL1848813T3 PL06733921T PL06733921T PL1848813T3 PL 1848813 T3 PL1848813 T3 PL 1848813T3 PL 06733921 T PL06733921 T PL 06733921T PL 06733921 T PL06733921 T PL 06733921T PL 1848813 T3 PL1848813 T3 PL 1848813T3
Authority
PL
Poland
Prior art keywords
cd1d
nkt cells
restricted nkt
activation
bacterial glycolipid
Prior art date
Application number
PL06733921T
Other languages
English (en)
Inventor
Luc Teyton
Albert Bendelac
Paul Savage
Original Assignee
Univ Brigham Young
Scripps Research Inst
Univ Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Brigham Young, Scripps Research Inst, Univ Chicago filed Critical Univ Brigham Young
Publication of PL1848813T3 publication Critical patent/PL1848813T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL06733921T 2005-01-28 2006-01-26 Aktywacja glikolipidem bakteryjnym komórek NKT podlegających restrykcji CD1d PL1848813T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64815305P 2005-01-28 2005-01-28
EP06733921.8A EP1848813B1 (en) 2005-01-28 2006-01-26 Bacterial glycolipid activation of cd1d-restricted nkt cells
PCT/US2006/002781 WO2006083671A2 (en) 2005-01-28 2006-01-26 Bacterial glycolipid activation of cd1d-restricted nkt cells

Publications (1)

Publication Number Publication Date
PL1848813T3 true PL1848813T3 (pl) 2013-09-30

Family

ID=36777772

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06733921T PL1848813T3 (pl) 2005-01-28 2006-01-26 Aktywacja glikolipidem bakteryjnym komórek NKT podlegających restrykcji CD1d

Country Status (12)

Country Link
US (1) US9295722B2 (pl)
EP (1) EP1848813B1 (pl)
JP (1) JP5053101B2 (pl)
AU (1) AU2006211485B2 (pl)
BR (1) BRPI0607299A2 (pl)
CA (1) CA2593715C (pl)
DK (1) DK1848813T3 (pl)
ES (1) ES2423005T3 (pl)
PL (1) PL1848813T3 (pl)
PT (1) PT1848813E (pl)
WO (1) WO2006083671A2 (pl)
ZA (1) ZA200706208B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
SI2056842T1 (sl) 2006-04-07 2013-02-28 The Scripps Research Institute Modificiran galaktosil-ceramid za zdravljenje kancerogenih obolenj
JP5564672B2 (ja) * 2006-06-30 2014-07-30 ザ スクリプス リサーチ インスティテュート アジュバント及びその使用方法
JP2010523724A (ja) * 2007-04-13 2010-07-15 アカデミア シニカ α−ガラクトシルセラミド類似体およびそれらの免疫療法剤としての使用
US8916164B2 (en) * 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
EP2058011A1 (en) * 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
AU2013202865B2 (en) * 2007-11-07 2015-03-19 Abivax Increase of immune response and targeting by antigens and/or drug linkage
EP2060252A1 (en) 2007-11-19 2009-05-20 Wittycell New formulation of galactosylceramide derivatives
US8211861B2 (en) * 2007-12-05 2012-07-03 Wittycell Compositions for and methods of enhancing the immune response to antigens
AU2009301167B2 (en) 2008-10-08 2015-10-29 Abivax Vaccine composition for use against influenza
AU2010217297A1 (en) * 2009-02-25 2011-10-20 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
JP6548579B2 (ja) * 2012-12-06 2019-07-24 ヴィクトリア リンク リミテッド コンジュゲート化合物
US9580758B2 (en) 2013-11-12 2017-02-28 Luc Montagnier System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
CN115666586A (zh) * 2020-04-23 2023-01-31 加州大学评议会 通过激活iNKT细胞清除衰老细胞
KR20230119224A (ko) * 2020-12-18 2023-08-16 로레알 스핑고모나스 속 박테리아 추출물
FR3117776B1 (fr) * 2020-12-18 2024-03-08 Oreal Extrait de bactérie du genreSphingomonas

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
TW261533B (pl) 1992-07-16 1995-11-01 Kirin Brewery
DE69328435T2 (de) 1992-10-22 2000-09-14 Kirin Brewery Neues sphingolglycolipid und verwendung davon
KR100281265B1 (ko) 1993-04-15 2001-02-01 마나배 게이사꾸 신규한 스핀고당지질 및 그의 사용
SK141695A3 (en) 1993-05-14 1996-10-02 Cytel Corp Analogous compound sialyl lex, pharmaceutical agent containing this compound and method of preparation of lactoseammoniacal salt
CN1768759A (zh) 1997-04-10 2006-05-10 麒麟麦酒株式会社 神经酰胺化合物在制备细胞活化剂中的应用
ZA988333B (en) * 1997-09-12 1999-03-23 Brigham & Woman S Hospital Synthetic antigens for CD1-restricted immune responses
WO2001082935A1 (fr) 2000-04-28 2001-11-08 Orient Cancer Therapy Co.,Ltd. Remedes contre le cancer
US20020071842A1 (en) * 2000-06-05 2002-06-13 Gumperz Jenny E. Soluble CD1 compositions and uses thereof
ES2586206T3 (es) * 2000-06-19 2016-10-13 Beth Israel Deaconess Medical Center Composiciones y métodos de anticuerpos monoclonales y policlonales específicos para subpoblaciones de linfocitos T
WO2001098317A2 (en) * 2000-06-22 2001-12-27 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
CA2453880A1 (en) 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
KR100549866B1 (ko) * 2001-08-22 2006-02-08 고려대학교 산학협력단 암치료 및 예방 제제
CA2469406A1 (en) 2001-11-06 2003-05-15 Orient Cancer Therapy Co., Ltd. Anticancer compositions
AU2003251518B2 (en) * 2002-06-13 2009-07-02 New York University Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
EP1611147A4 (en) 2003-03-20 2007-10-17 Univ Brigham Young 6 "amino-6" -DEOXYGALACTOSYLCERAMIDE
GB0314682D0 (en) 2003-06-24 2003-07-30 Isis Innovation Materials and methods relating to the modulation of T cell response to soluble antigen
JP5005541B2 (ja) 2004-09-03 2012-08-22 ザ ユニヴァーシティー オヴ シカゴ Ｎｋｔ細胞の活性化方法
SI2056842T1 (sl) 2006-04-07 2013-02-28 The Scripps Research Institute Modificiran galaktosil-ceramid za zdravljenje kancerogenih obolenj
JP5564672B2 (ja) 2006-06-30 2014-07-30 ザ スクリプス リサーチ インスティテュート アジュバント及びその使用方法

Also Published As

Publication number Publication date
ES2423005T3 (es) 2013-09-17
WO2006083671A2 (en) 2006-08-10
EP1848813A2 (en) 2007-10-31
JP2008528608A (ja) 2008-07-31
EP1848813B1 (en) 2013-04-10
WO2006083671B1 (en) 2007-04-12
BRPI0607299A2 (pt) 2009-08-25
US9295722B2 (en) 2016-03-29
AU2006211485B2 (en) 2011-04-14
US20080279894A1 (en) 2008-11-13
JP5053101B2 (ja) 2012-10-17
DK1848813T3 (da) 2013-07-15
CA2593715C (en) 2015-05-05
CA2593715A1 (en) 2006-08-10
ZA200706208B (en) 2008-04-30
AU2006211485A1 (en) 2006-08-10
PT1848813E (pt) 2013-07-15
EP1848813A4 (en) 2008-07-09
WO2006083671A3 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
EP1848813A4 (en) ACTIVATION OF BACTERIAL GLYCOLIPIDES OF CD1D-DEPLETED NKT CELLS
HK1209648A1 (en) Novel sulfated oligosaccharide derivatives
EP1889172A4 (en) SYSTEM FOR SENDING MESSAGES SPECIFIC TO PATIENTS
IL197444A0 (en) Cell culture improvements
EP1844380B8 (en) Improvements in or relating to ablutionary installations
GB0613756D0 (en) Cell culture medium
EP2272854A4 (en) NEW GLYCOLIPIDE AND USE THEREOF
ZA200708100B (en) Oligosaccharide mixture
EP1913126A4 (en) Co-culture bioreactor system
ZA201007022B (en) Carbohydrate gel
EP2129692A4 (en) ACTIVATION OF CELLS WITH HUMAN ANTIGENES BY CLEC-6
GB0717796D0 (en) Cell culture chamber
EP2154234A4 (en) TRANSPARENT SOLID SOAP
GB0715183D0 (en) Surfactants not toxic to bacteria
EP1997884A4 (en) NEW HUMAN T-CELL POPULATION
EP1899910A4 (en) USING MESSAGES TO ENHANCE CRM FUNCTIONALITY
EP2027865A4 (en) LIPOSOME HAVING A LIPIDIC MEMBRANE CONTAINING A BACTERIAL CELLULAR COMPONENT
EP2185684B8 (de) Kollagenhaltiger zellträger
GB0606671D0 (en) Cell Culture
SI1848813T1 (sl) Aktiviranje bakterijskega glikopida s CD1D omenjenih NKT-celic
GB0620265D0 (en) Closed cell
GB0609797D0 (en) Adhesive solution for application to the skin
EP1866071A4 (en) PERMETHYLATION OF OLIGOSACCHARIDES
GB0509318D0 (en) TCR-independent activation of T cells
EP1716857A4 (en) COMPOSITION FOR ACTIVATION OF NKT CELLS